IL13RA2 and glioblastoma: Interleukin-13 receptor subunit alpha-2 (IL13Rα2) is another attractive target as it is expressed at a higher frequency of 40–76% in IDH-wildtype GBM, but systemic delivery carries a higher risk of complications due to its minimal expression on normal tissue [59,60,61,62,63,64].